Degeneration of dopaminergic neurons due to metabolic alterations and Parkinson’s disease
The rates of metabolic diseases, such as type 2 diabetes mellitus (T2DM), obesity, and cardiovascular disease, markedly increase with age. In recent years, studies have reported an association between metabolic changes and various pathophysiological mechanisms in the central nervous system (CNS) in...
Main Authors: | Juhyun eSong, JONGPIL eKIM |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-03-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fnagi.2016.00065/full |
Similar Items
-
Celastrol Inhibits Dopaminergic Neuronal Death of Parkinson’s Disease through Activating Mitophagy
by: Ming-Wei Lin, et al.
Published: (2019-12-01) -
Mitochondrial Phenotypes in Parkinson’s Diseases—A Focus on Human iPSC-Derived Dopaminergic Neurons
by: Leonie M. Heger, et al.
Published: (2021-12-01) -
Roles of FGF20 in dopaminergic neurons and Parkinson’s disease
by: Nobuyuki eItoh, et al.
Published: (2013-05-01) -
Downregulation of Ambra1 by altered DNA methylation exacerbates dopaminergic neuron damage in a fenpropathrin-induced Parkinson-like mouse model
by: Songzhe He, et al.
Published: (2024-02-01) -
Understanding miRNA Based Gene Regulation in Parkinson’s Disease: An in silico Approach
by: Surya Narayan Rath, et al.
Published: (2020-03-01)